Abstract:Schizophrenia and related mood disorders are complex psychiatric disorders that affect ~2% of the population ( 1 Brandon N.J. Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci. 2011; 12: 707-722 Google Scholar , 2 Moghaddam B. Javitt D. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012; 37: 4-15 Google Scholar ). The fortuitous finding of chlorpromazine and other phenothiazines in the early 1950s and subsequent development of clozapine and related antipsychotic drugs ameliorated a subset of syndromes of psychosis and resulted in deinstitutionalization of many patients with psychiatric disorders. The drugs seem to benefit patients by modulating dopaminergic or serotoninergic function, or both. The exact mechanisms of action of the drugs are unknown. There are still no good answers 50 years after the discovery of these drugs as to why the medications fail to treat the negative symptoms and cognitive deficits, and this lack of answers has hampered the development of more effective medications ( 1 Brandon N.J. Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci. 2011; 12: 707-722 Google Scholar , 2 Moghaddam B. Javitt D. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012; 37: 4-15 Google Scholar ). A comprehensive understanding of the etiopathology of psychiatric disorders is urgently needed for developing improved medications. Accumulating research findings have fostered a hypothesis that aberrant glutamatergic transmission, particularly aberrant N-methyl-D-aspartate receptor (NMDAR)–mediated glutamate transmission, may be responsible for schizophrenia and related psychiatric disorders ( 1 Brandon N.J. Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci. 2011; 12: 707-722 Google Scholar , 2 Moghaddam B. Javitt D. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012; 37: 4-15 Google Scholar , 3 Harrison P.J. Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry. 2005; 10: 40-68 Google Scholar , 4 Lau C.G. Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci. 2007; 8: 413-426 Google Scholar ). The initial evidence has emerged from administration of NMDAR antagonists, including phencyclidine and ketamine, which elicit psychotic symptoms and cognitive dysfunction similar to those of schizophrenia and related psychiatric disorders and aggravate the psychotic symptoms in patients with the disorders. The effects of NMDAR antagonists persist in the absence of activity of monoamines. Additionally, genetically reducing NMDAR expression in interneurons produces schizophrenia-like phenotypes. Finally, more recent genetic studies have linked numerous genes, including the disrupted in schizophrenia 1 gene (DISC1), with the disorders, and many of those molecules have been implicated in regulation of glutamatergic transmission ( 3 Harrison P.J. Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry. 2005; 10: 40-68 Google Scholar , 4 Lau C.G. Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci. 2007; 8: 413-426 Google Scholar ). Together, these findings have led to the prevailing hypothesis that hypofunction of NMDARs, particularly hypofunction of NMDARs in interneurons, causes progression and symptoms of schizophrenia and related psychiatric disorders. Regulation of N-Methyl-D-Aspartate Receptors by Disrupted-in-Schizophrenia-1Biological PsychiatryVol. 75Issue 5PreviewGenetic studies have implicated disrupted-in-schizophrenia-1 (DISC1) as a risk factor for a wide range of mental conditions, including schizophrenia. Because N-methyl-D-aspartate receptor (NMDAR) dysfunction has been strongly linked to the pathophysiology of these conditions, we examined whether the NMDAR is a potential target of DISC1. Full-Text PDF

Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia

Glutamatergic dysfunction in Schizophrenia

NMDA Receptor Hypofunction Induces Dysfunctions of Energy Metabolism and Semaphorin Signaling in Rats: a Synaptic Proteome Study.

Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia

Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment

Dopamine and glutamate in schizophrenia: biology, symptoms and treatment

Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders

The Role Of N-Methyl-D-Aspartate Receptors And Metabotropic Glutamate Receptor 5 In The Prepulse Inhibition Paradigms For Studying Schizophrenia: Pharmacology, Neurodevelopment, And Genetics

NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders

Finding the right dose: NMDAR modulating treatments for cognitive and plasticity deficits in schizophrenia and the role of pharmacodynamic target engagement

Targeting NMDA Receptor Pathways

DISC1 Dynamically Regulates Synaptic N-Methyl-D-Aspartate Responses in Excitatory Neurons

Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways

N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity

The genetics of schizophrenia: glutamate not dopamine?

NMDA Receptors: Distribution, Role, and Insights into Neuropsychiatric Disorders

Dysregulated Signaling at Postsynaptic Density: A Systematic Review and Translational Appraisal for the Pathophysiology, Clinics, and Antipsychotics' Treatment of Schizophrenia

Targeting the dysfunction of glutamate receptors for the development of novel antidepressants

Altered neuronal excitability underlies impaired hippocampal function in an animal model of psychosis

Histamine H2 receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia